2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Atkins M, Jegede O, Haas N, McDermott D, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Ornstein M, Hurwitz M, Peace D, Signoretti S, Denize T, Cimadamore A, Wu C, Braun D, Einstein D, Catalano P, Hammers H. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B). Journal For ImmunoTherapy Of Cancer 2023, 11: e004780. PMID: 36948504, PMCID: PMC10040058, DOI: 10.1136/jitc-2022-004780.Peer-Reviewed Original ResearchConceptsNivolumab/ipilimumabObjective response rateNon-clear cell renal cell carcinomaTreatment-naïve patientsCell renal cell carcinomaProgressive diseaseRenal cell carcinomaNivolumab monotherapyStable diseaseCell carcinomaAdvanced non-clear cell renal cell carcinomaMedian progression-free survivalTreatment-related adverse eventsDeath ligand 1 (PD-L1) expressionLigand 1 expressionPhase II studyProgression-free survivalWeeks of treatmentSymptomatic disease progressionEligible patientsSalvage therapyB patientsII studySalvage treatmentSarcomatoid features
1999
Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer
Smith M, Kantoff P, Oh W, Elson G, Manola J, McMullin M, Jacobsen J, Brufsky A, Kaufman D. Phase II Trial of the Antiestrogen Toremifene for Androgen‐Independent Prostate Cancer. The Prostate Journal 1999, 1: 185-189. DOI: 10.1046/j.1525-1411.1999.14003.x.Peer-Reviewed Original ResearchProstate specific antigenSerum testosterone levelsNonresponse to treatmentAndrogen-independent CaPTestosterone levelsAntiestrogen toremifeneProstate cancerPSA decreaseRising prostate specific antigenProstate specific antigen levelsAndrogen-independent prostate cancerResponse criteriaCastrate testosterone levelsSecondary hormonal therapyTreated with toremifeneMetastatic prostate cancerSymptomatic disease progressionMalignant prostatic epitheliumPhase II trialDisease-related symptomsAntiandrogen withdrawalAndrogen deprivationProstate epitheliumHormone therapyII trial
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply